Related Experiment Video

Updated: Sep 20, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Outcome and management of hepatitis C in liver transplant recipients

Susan E Chan1, Hugo R Rosen

  • 1Division of Gastroenterology/Hepatology, Portland Veterans Affairs Medical Center, Portland, Oregon 97207, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|September 5, 2003
PubMed

Insights

Hepatitis C virus (HCV) reinfection after liver transplant is common, leading to graft injury and higher mortality. Identifying high-risk patients is crucial for better treatment strategies.

Area of Science:

  • Hepatology
  • Transplantation Immunology
  • Virology

Background:

  • Hepatitis C virus (HCV)-related cirrhosis is a primary reason for liver transplantation.
  • HCV allograft reinfection occurs in all patients with pre-transplant viremia, causing hepatitis in 50-80%.

Purpose of the Study:

  • To highlight the increased mortality in HCV-positive liver transplant recipients.
  • To address the controversy surrounding retransplantation for this patient group.
  • To emphasize the need for improved understanding of risk factors for HCV-induced graft injury.

Main Methods:

  • Review of recent data on HCV-positive liver transplant recipients.
  • Analysis of outcomes including mortality and graft injury.
  • Evaluation of current antiviral therapy limitations.

Main Results:

  • HCV-positive liver transplant recipients face significantly higher mortality rates.
  • Retransplantation for HCV recurrence is a complex and debated issue.
  • Current antiviral treatments show limited efficacy and tolerability.

Conclusions:

  • Improved understanding of risk factors for severe HCV graft injury is essential.
  • Optimizing treatment strategies for HCV recurrence post-transplant is a critical need.
  • Further research is required to improve outcomes for HCV-positive liver transplant patients.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...